105 related articles for article (PubMed ID: 38727048)
1. Glycyrrhetinic Acid as a Hepatocyte Targeting Ligand-Functionalized Platinum(IV) Complexes for Hepatocellular Carcinoma Therapy and Overcoming Multidrug Resistance.
Huang X; Li G; Li H; Zhong W; Jiang G; Cai J; Xiong Q; Wu C; Su K; Huang R; Xu S; Liu Z; Wang M; Wang H
J Med Chem; 2024 May; 67(10):8020-8042. PubMed ID: 38727048
[TBL] [Abstract][Full Text] [Related]
2. Novel NF-κB Inhibitor-Conjugated Pt(IV) Prodrug to Enable Cancer Therapy through ROS/ER Stress and Mitochondrial Dysfunction and Overcome Multidrug Resistance.
Wang M; Li G; Jiang G; Cai J; Liu Z; Huang R; Huang X; Wang H
J Med Chem; 2024 Apr; 67(8):6218-6237. PubMed ID: 38573870
[TBL] [Abstract][Full Text] [Related]
3. Dual-targeting antitumor conjugates derived from platinum(IV) prodrugs and microtubule inhibitor CA-4 significantly exhibited potent ability to overcome cisplatin resistance.
Huang X; Wang M; Wang C; Hu W; You Q; Yang Y; Yu C; Liao Z; Gou S; Wang H
Bioorg Chem; 2019 Nov; 92():103236. PubMed ID: 31494328
[TBL] [Abstract][Full Text] [Related]
4. New Platinum(II) agent induces bimodal death of apoptosis and autophagy against A549 cancer cell.
Wang FY; Huang KB; Feng HW; Chen ZF; Liu YN; Liang H
Free Radic Biol Med; 2018 Dec; 129():418-429. PubMed ID: 30266678
[TBL] [Abstract][Full Text] [Related]
5. Novel Pt(IV) complexes containing salvigenin ligand reverse cisplatin-induced resistance by inhibiting Rap1b-mediated cancer cell stemness in esophageal squamous cell carcinoma treatments.
Zhao J; Wu K; Yang Y; Liu D; Zhang C; Li X
Bioorg Chem; 2024 Jun; 147():107384. PubMed ID: 38643568
[TBL] [Abstract][Full Text] [Related]
6. Targeting RAS-RAF pathway significantly improves antitumor activity of Rigosertib-derived platinum(IV) complexes and overcomes cisplatin resistance.
Liu Z; Wang M; Wang H; Fang L; Gou S
Eur J Med Chem; 2020 May; 194():112269. PubMed ID: 32248002
[TBL] [Abstract][Full Text] [Related]
7. Hepatocellular Carcinoma Targeting and Pharmacodynamics of Paclitaxel Nanoliposomes Modified by Glycyrrhetinic Acid and Ferric Tetroxide.
Zhao L; Liang L; Guo M; Li M; Yu X; Wang Y; Wang Y
Curr Top Med Chem; 2021 Oct; 21(14):1268-1284. PubMed ID: 34620053
[TBL] [Abstract][Full Text] [Related]
8. Construction of Dual Stimuli-Responsive Platinum(IV) Hybrids with NQO1 Targeting Ability and Overcoming Cisplatin Resistance.
Fang L; Qin X; Zhao J; Gou S
Inorg Chem; 2019 Feb; 58(3):2191-2200. PubMed ID: 30657321
[TBL] [Abstract][Full Text] [Related]
9. Platinum-Based Modification of Styrylbenzylsulfones as Multifunctional Antitumor Agents: Targeting the RAS/RAF Pathway, Enhancing Antitumor Activity, and Overcoming Multidrug Resistance.
Liu Z; Wang M; Wang H; Fang L; Gou S
J Med Chem; 2020 Jan; 63(1):186-204. PubMed ID: 31820986
[TBL] [Abstract][Full Text] [Related]
10. Pt(IV) prodrugs containing microtubule inhibitors displayed potent antitumor activity and ability to overcome cisplatin resistance.
Li L; Huang X; Huang R; Gou S; Wang Z; Wang H
Eur J Med Chem; 2018 Aug; 156():666-679. PubMed ID: 30031977
[TBL] [Abstract][Full Text] [Related]
11. Astragaloside IV enhances cisplatin chemosensitivity in hepatocellular carcinoma by suppressing MRP2.
Qu X; Gao H; Zhai J; Sun J; Tao L; Zhang Y; Song Y; Hu T
Eur J Pharm Sci; 2020 May; 148():105325. PubMed ID: 32259679
[TBL] [Abstract][Full Text] [Related]
12. Antitumor platinum(II) complexes of N-monoalkyl-1R, 2R-diaminocyclohexane derivatives with alkyl groups as hindrance.
Sun Y; Yin R; Gou S; Zhaojian
J Inorg Biochem; 2012 Jul; 112():68-76. PubMed ID: 22561544
[TBL] [Abstract][Full Text] [Related]
13. Glycyrrhetinic acid derivatives containing aminophosphonate ester species as multidrug resistance reversers that block the NF-κB pathway and cell proliferation.
Jin L; Zhang B; Hua S; Ji M; Huang X; Huang R; Wang H
Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3700-3707. PubMed ID: 30528976
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin and curcumin co-loaded nano-liposomes for the treatment of hepatocellular carcinoma.
Cheng Y; Zhao P; Wu S; Yang T; Chen Y; Zhang X; He C; Zheng C; Li K; Ma X; Xiang G
Int J Pharm; 2018 Jul; 545(1-2):261-273. PubMed ID: 29730175
[TBL] [Abstract][Full Text] [Related]
15. Knockdown of THOC1 reduces the proliferation of hepatocellular carcinoma and increases the sensitivity to cisplatin.
Cai S; Bai Y; Wang H; Zhao Z; Ding X; Zhang H; Zhang X; Liu Y; Jia Y; Li Y; Chen S; Zhou H; Liu H; Yang C; Sun T
J Exp Clin Cancer Res; 2020 Jul; 39(1):135. PubMed ID: 32669125
[TBL] [Abstract][Full Text] [Related]
16. Conjugation of platinum(IV) complexes with chlorambucil to overcome cisplatin resistance via a "joint action" mode toward DNA.
Qin X; Fang L; Chen F; Gou S
Eur J Med Chem; 2017 Sep; 137():167-175. PubMed ID: 28586717
[TBL] [Abstract][Full Text] [Related]
17. A conveniently synthesized Pt (IV) conjugated alginate nanoparticle with ligand self-shielded property for targeting treatment of hepatic carcinoma.
Wang X; Chang Z; Nie X; Li Y; Hu Z; Ma J; Wang W; Song T; Zhou P; Wang H; Yuan Z
Nanomedicine; 2019 Jan; 15(1):153-163. PubMed ID: 30308299
[TBL] [Abstract][Full Text] [Related]
18. Platinum(IV) complexes conjugated with phenstatin analogue as inhibitors of microtubule polymerization and reverser of multidrug resistance.
Huang X; Huang R; Gou S; Wang Z; Liao Z; Wang H
Bioorg Med Chem; 2017 Sep; 25(17):4686-4700. PubMed ID: 28728896
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and in vitro and in vivo antitumor activity of a series of trans platinum antitumor complexes.
Kelland LR; Barnard CF; Evans IG; Murrer BA; Theobald BR; Wyer SB; Goddard PM; Jones M; Valenti M; Bryant A
J Med Chem; 1995 Aug; 38(16):3016-24. PubMed ID: 7636864
[TBL] [Abstract][Full Text] [Related]
20. Toward overcoming cisplatin resistance via sterically hindered platinum(II) complexes.
Yu H; Gou S; Wang Z; Chen F; Fang L
Eur J Med Chem; 2016 May; 114():141-52. PubMed ID: 26974381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]